Vir Biotechnology (VIR) Cash from Financing Activities (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Cash from Financing Activities data on file, last reported at $162.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 27077.76% year-over-year to $162.5 million; the trailing twelve-month figure through Mar 2026 stood at $165.7 million (up 3328.01% YoY), and the FY2025 full-year result was $3.8 million, down 13.74% from the prior year.
• Cash from Financing Activities advanced to $162.5 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $162.5 million in Q1 2026 to a low of $31000.0 in Q3 2024.
• A 5-year average of $12.5 million and a median of $2.0 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 93.52% in 2024 and soared 27077.76% in 2026, its largest moves.
• Tracing VIR's Cash from Financing Activities over 5 years: stood at $2.0 million in 2022, then decreased by 16.46% to $1.7 million in 2023, then slipped by 24.82% to $1.3 million in 2024, then retreated by 17.74% to $1.0 million in 2025, then surged by 15542.25% to $162.5 million in 2026.
• Business Quant data shows VIR's Cash from Financing Activities at $162.5 million in Q1 2026, $1.0 million in Q4 2025, and $102000.0 in Q3 2025.